# **GUJARAT INJECT KERALA LIMITED**

CIN: L24231KL1991PLC005926

Regd Office: Bldg No. XVII/1103 at Sarayu Arcade Satrapadi, Kanjikode, Palakkad – 678 621

Administrative Office: SB-06, Paradise Complex, Opp. M.S. University, Sayajiganj, Vadodara – 390 005

Phones: 09898593314, 09712193314

E-Mail: murlisnair9032@gmail.com, admin@gikl.comWebsite: www.gujaratinject.com

Date: August 12, 2021

To, BSE Limited PhirozeJeejeebhoy Towers, Dalal Street, Mumbai - 400 001.

Dear Sir,

Sub: Submission of Unaudited Financial Result of the Company for the quarter ended on June 30, 2021

Ref: Gujarat Inject Kerala Limited (Security ID: GUJINJEC, Security Code: 524238)

In reference to captioned subject, we hereby submit the unaudited financial result for the quarter ended on June 30, 2021 along with Limited Review Report.

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,

For, Gujarat Inject Kerala Limited

Murli Nair

Whole Time Director

DIN: 02243039

Place: Vadodara

For, GUJARAT INJECT KERELA LIMITED

Director, Authorised Signatory

# **GUJARAT INJECT KERALA LIMITED**

CIN: 124231KI 1991PLC005926

Registered Office: Building No. XVII/1103 at Sarayu Arcade Satrapadi, Kanjikode, Palakkad - 678 621 Administrative Office: SB-06, Paradise Complex, Opp. M.S. University, Sayajiganj, Vadodara - 390 005

### Statement of Standalone Financial Results for the quarter ended on June 30, 2021

	nercon Completion	(* In Lakh except per share dat Quarter Ended Year Ended				
	Particulars	30/06/2021	31/03/2021	30/06/2020	31/03/2021	
Α	Date of start of reporting period	01/04/2021	01/01/2021	01/04/2020	01/04/2020	
В		30/06/2021	31/03/2021	30/06/2020	31/03/2021	
C	Date of end of reporting period		Audited	Unaudited	Audited	
0.00	Whether results are audited or unaudited	Unaudited	0113101311010	The second second		
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	
_!	Revenue From Operations		1.16			
	Net sales or Revenue from Operations	1.07	1.15		1.1	
Ш	Other Income	0.20	0.20	0.15	3,0	
Ш	Total Income (I+II)	1.27	1.35	0.15	1.9	
IV	Expenses	- ANNENES			(-1)	
	Cost of materials consumed	0.94	0.89		0.8	
	Purchases of stock-in-trade					
	Changes in inventories of finished goods, work-in-progress and stock-in-trade			*		
	Employee benefit expense	0.26	0.12	•	0.2	
	Finance Costs		11.09		11.0	
(f)	Depreciation and amortisation expense				790	
(g)	Other Expenses	0.10	0.13	0.11	0.2	
	Total expenses (IV)	1.30	12.23	0.11	12.4	
٧	Profit/(loss) before exceptional items and tax (III-IV)	(0.03)	(10.88)	0.04	(10.5	
VI	Exceptional items	7 <u>21</u>				
VII	Profit (loss) after exceptional items and before Tax (V-VI)	(0.03)	(10.88)	0.04	(10.5	
VIII	Tax Expense				•	
(a)	Current Tax					
(b)	(Less):- MAT Credit					
(c)	Current Tax Expense Relating to Prior years	780				
(d)	Deferred Tax (Asset)/Liabilities	-				
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	(0.03)	(10.88)	0.04	(10.5	
X	Profit/(loss) from discontinued operations	-	(111117)			
XI	Tax expenses of discontinued operations		-			
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)					
XIII A	Profit(Loss) For Period Before Minority Interest	(0.03)	(10.88)	0.04	(10.5	
XIII B	Share Of Profit / Loss of Associates and joint ventures accounted for using equity	(0.03)	(10.00)	0.04	(10.3	
Alli D	method					
XIII C	Profit/Loss Of Minority Interset	141				
XIV	Profit (Loss) for the period (XIII A + XIII B + XIII C)	(0.03)	(10.88)	0.04	(10.5	
XV	Other Comprehensive Income	(0.00)	(10,00)	3,53	(13.3	
~,	a. i). Items that will not be reclassifled to profit or loss				-	
	ii). Income tax relating to items that will not be reclassified to profit or loss					
	b. i). Item that will be reclassifed to profit or loss	-	-	4		
	ii). Income tax relating to items that will be reclassifed to profit or loss		-			
	Total Comprehensive income	-				
	Total Comprehensive income [Comprising Profit for the Period and Other	(0.03)	(10.88)	0.04	(10.5	
XVI	comprehensive income] (XIV+XV)	(0.03)	(10.00)	0.04	(10.5	
XVII	Details of equity share capital					
AVII	Paid-up equity share capital	488.48	488.48	488.48	488.4	
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10	
MIM	port of the second second second second of the control of the second sec	NS. 10/-	KS. 107-	K5, 107-	K5. 10	
XIX	Earnings per share					
(a)	Earnings per share (not annualised for quarter ended)		12.22			
	Basic earnings (loss) per share from continuing operation	(0.00)	(0.22)	0.00	(0.2	
	Diluted earnings (loss) per share from continuing operation	(0.00)	(0.22)	0.00	(0.2	
(b)	Earnings per share (not annualised for quarter ended)					
	Basic earnings (loss) per share from discontinued operation	*				
	Diluted earnings (loss) per share from discontinued operation	1.0	1.50	•	•	
(c)	Earnings per share (not annualised for quarter ended)					
	Basic earnings (loss) per share from continuing and discotinued operations	(0.00)	(0.22)	0.00	(0.2	
	Diluted earnings (loss) per share continuing and discotinued operations	(0.00)	(0.22)	0.00	(0.2	

For, GUJARAT INJECT KERELA LIMITED

Director, Authorised Signatory



## **GUJARAT INJECT KERALA LIMITED**

CIN: L24231KL1991PLC005926

Registered Office: Building No. XVII/1103 at Sarayu Arcade Satrapadi, Kanjikode, Palakkad - 678 621 Administrative Office: SB-06, Paradise Complex, Opp. M.S. University, Sayajiganj, Vadodara - 390 005

#### Statement of Standalone Financial Results for the quarter ended on June 30, 2021

('In Lakh except per share data)

Particulars -			Quarter Ended		
			31/03/2021	30/06/2020	31/03/2021
A	Date of start of reporting period	01/04/2021	01/01/2021	01/04/2020	01/04/2020
В	Date of end of reporting period	30/06/2021	31/03/2021	30/06/2020	31/03/2021
С	Whether results are audited or unaudited	Unaudited	Audited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone

#### Notes on Financial Results:-

- 1 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.
- 2 The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
  - 3 The Audit Committee has reviewed the above results and the Board of Directors has approved the above results and its release at their respective meetings held on August 12, 2021.
  - The Statutory Auditors of the Company have carried out limited review of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.

For, GUJARAT INJECT KERALA LIMITED

For, GUJARAT INJECT KERELA LIMITED

Director, Authorised Signatory

Murali Nair Whole-Time Director

DIN 02243039

August 12, 2021

Vadodara



## S. MANDAWAT & CO.

### Chartered Accountants

913, Sahjanand Shopping Centre ,Opp. Rajasthan Hindi High School Shahibaug Road- Ahmedabad - 380004 Phone : (O) 25620913 (M) 9426072909 Email : skmandawat@yahoo.co.in

Limited Review Report on quarterly standalone financial results of Gujarat Inject Kerala Limitedpursuant to the Regulation 33 of the SEBI(LODR) Regulations, 2015 as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019

To,

The Board of Directors of Gujarat Inject Kerala Limited,

SB-06, Paradise Complex, Opp. M.S. University, Sayajiganj, Vadodara - 390 005

We have reviewed the accompanyingstatement of standalone unaudited financial results of Gujarat Inject Kerala Limited for the Quarter ended June 30, 2021. This statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 (the Listing Regulation, 2015), as amended. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s. S. Mandawat& Co. Chartered Accountants

Firm's Registration No: 118330W

CA Subhash Chandra Mandawat

**Partner** 

Membership No. 102708

UDIN:21102708AAAAFA5266

Place: Ahmedabad Date: 12-08-2021

